Loading…
Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics
Enhanced sister chromatid exchange (SCE) frequency by either melphalan (Mel) or epirubicin (Epir) was observed when human lymphocytes were exposed in vitro to 9‐nitro‐20(S)‐camptothecin (9NC). A correlation was observed between the magnitude of the SCE response and the depression of the cell prolife...
Saved in:
| Published in: | Teratogenesis, carcinogenesis, and mutagenesis carcinogenesis, and mutagenesis, 2000, Vol.20 (3), p.141-146 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3705-3dbd626b74d5781ad362172069ed8b6586f4ec50e18df3c4d8067244de5d0c493 |
| container_end_page | 146 |
| container_issue | 3 |
| container_start_page | 141 |
| container_title | Teratogenesis, carcinogenesis, and mutagenesis |
| container_volume | 20 |
| creator | Karaberis, E. Mourelatos, D. |
| description | Enhanced sister chromatid exchange (SCE) frequency by either melphalan (Mel) or epirubicin (Epir) was observed when human lymphocytes were exposed in vitro to 9‐nitro‐20(S)‐camptothecin (9NC). A correlation was observed between the magnitude of the SCE response and the depression of the cell proliferation index. The antitumor activity of Mel and of 9NC was tested on leukemia P‐388‐bearing mice. The two chemicals in combination enhance antitumor activity in a synergistic manner. Therefore, the in vivo antitumor effect of Mel in conjunction with 9NC appears to correlate well with the in vitro synergistic effect on SCE induction caused by the combined Mel plus 9NC treatment. Teratogenesis Carcinog. Mutagen. 20:141–146, 2000. © 2000 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/(SICI)1520-6866(2000)20:3<141::AID-TCM5>3.0.CO;2-D |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17537310</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17537310</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3705-3dbd626b74d5781ad362172069ed8b6586f4ec50e18df3c4d8067244de5d0c493</originalsourceid><addsrcrecordid>eNp9kF1v0zAUhi0EYmXwF1AuENouUo4_kxaENNKxFW2Ujw0uj1zbYYF8lNgV9N_j0KpDAnFhW0d6_Pr1Q8iUwpgCsGdHH-fF_JhKBqnKlTpiAHDMYMpfUEGn05P5LL0qLuVLPoZxsXjO0tkdMtrjd8kIWAYpZ5QekAfefwWgQCm7Tw4o5AwEEyNyfdre6NY4m5hN6L641oXKJLq1cYUqrJuuT1xZOhN8stwkk7StQt8Z3axCF26cqdo93LpuVWsf7_uH5F6pa-8e7c5Dcv369Ko4Ty8WZ_Pi5CI1PAOZcru0iqllJqzMcqotV4xmDNTE2XypZK5K4YwER3NbciNsDipjQlgnLRgx4Yfk6TZ31Xff184HbCpvXF3rWGbtkWaSZ5xCBD9sQdN33veuxFVfNbrfIAUcZCMOsnGwh4M9HGTHDTlG2YhRNg6y4wxYLJDhLIY-3r2-XjbO_hG5tRuBJztAe6Prso-mK3_L8fhFNrkt96Oq3eavZv8t9o9ev-cYmm5DKx_cz32o7r-hyngm8fPbM3wn3ss3l-ev8BP_BQr9tJQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17537310</pqid></control><display><type>article</type><title>Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Karaberis, E. ; Mourelatos, D.</creator><creatorcontrib>Karaberis, E. ; Mourelatos, D.</creatorcontrib><description>Enhanced sister chromatid exchange (SCE) frequency by either melphalan (Mel) or epirubicin (Epir) was observed when human lymphocytes were exposed in vitro to 9‐nitro‐20(S)‐camptothecin (9NC). A correlation was observed between the magnitude of the SCE response and the depression of the cell proliferation index. The antitumor activity of Mel and of 9NC was tested on leukemia P‐388‐bearing mice. The two chemicals in combination enhance antitumor activity in a synergistic manner. Therefore, the in vivo antitumor effect of Mel in conjunction with 9NC appears to correlate well with the in vitro synergistic effect on SCE induction caused by the combined Mel plus 9NC treatment. Teratogenesis Carcinog. Mutagen. 20:141–146, 2000. © 2000 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-3211</identifier><identifier>EISSN: 1520-6866</identifier><identifier>DOI: 10.1002/(SICI)1520-6866(2000)20:3<141::AID-TCM5>3.0.CO;2-D</identifier><identifier>PMID: 10820424</identifier><identifier>CODEN: TCMUD8</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>9-nitro-20(S)-camptothecin ; 9-nitrocamtothecin ; Animals ; antineoplastic activity ; Antineoplastic agents ; Antineoplastic Agents, Phytogenic - pharmacology ; Antineoplastic Agents, Phytogenic - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Camptothecin - administration & dosage ; Camptothecin - analogs & derivatives ; Camptothecin - pharmacology ; Camptothecin - therapeutic use ; Cell Division - drug effects ; cell kinetics ; Chemotherapy ; Drug Screening Assays, Antitumor ; epirubicin ; Epirubicin - administration & dosage ; Epirubicin - pharmacology ; Epirubicin - therapeutic use ; Humans ; Leukemia P388 - drug therapy ; Lymphocytes - drug effects ; Lymphocytes - ultrastructure ; Medical sciences ; melphalan ; Melphalan - administration & dosage ; Melphalan - pharmacology ; Melphalan - therapeutic use ; Mice ; Pharmacology. Drug treatments ; SCE ; Sister Chromatid Exchange - drug effects</subject><ispartof>Teratogenesis, carcinogenesis, and mutagenesis, 2000, Vol.20 (3), p.141-146</ispartof><rights>Copyright © 2000 Wiley‐Liss, Inc.</rights><rights>2000 INIST-CNRS</rights><rights>Copyright 2000 Wiley-Liss, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3705-3dbd626b74d5781ad362172069ed8b6586f4ec50e18df3c4d8067244de5d0c493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1365829$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10820424$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karaberis, E.</creatorcontrib><creatorcontrib>Mourelatos, D.</creatorcontrib><title>Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics</title><title>Teratogenesis, carcinogenesis, and mutagenesis</title><addtitle>Teratog. Carcinog. Mutagen</addtitle><description>Enhanced sister chromatid exchange (SCE) frequency by either melphalan (Mel) or epirubicin (Epir) was observed when human lymphocytes were exposed in vitro to 9‐nitro‐20(S)‐camptothecin (9NC). A correlation was observed between the magnitude of the SCE response and the depression of the cell proliferation index. The antitumor activity of Mel and of 9NC was tested on leukemia P‐388‐bearing mice. The two chemicals in combination enhance antitumor activity in a synergistic manner. Therefore, the in vivo antitumor effect of Mel in conjunction with 9NC appears to correlate well with the in vitro synergistic effect on SCE induction caused by the combined Mel plus 9NC treatment. Teratogenesis Carcinog. Mutagen. 20:141–146, 2000. © 2000 Wiley‐Liss, Inc.</description><subject>9-nitro-20(S)-camptothecin</subject><subject>9-nitrocamtothecin</subject><subject>Animals</subject><subject>antineoplastic activity</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Phytogenic - pharmacology</subject><subject>Antineoplastic Agents, Phytogenic - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Camptothecin - administration & dosage</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Camptothecin - pharmacology</subject><subject>Camptothecin - therapeutic use</subject><subject>Cell Division - drug effects</subject><subject>cell kinetics</subject><subject>Chemotherapy</subject><subject>Drug Screening Assays, Antitumor</subject><subject>epirubicin</subject><subject>Epirubicin - administration & dosage</subject><subject>Epirubicin - pharmacology</subject><subject>Epirubicin - therapeutic use</subject><subject>Humans</subject><subject>Leukemia P388 - drug therapy</subject><subject>Lymphocytes - drug effects</subject><subject>Lymphocytes - ultrastructure</subject><subject>Medical sciences</subject><subject>melphalan</subject><subject>Melphalan - administration & dosage</subject><subject>Melphalan - pharmacology</subject><subject>Melphalan - therapeutic use</subject><subject>Mice</subject><subject>Pharmacology. Drug treatments</subject><subject>SCE</subject><subject>Sister Chromatid Exchange - drug effects</subject><issn>0270-3211</issn><issn>1520-6866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNp9kF1v0zAUhi0EYmXwF1AuENouUo4_kxaENNKxFW2Ujw0uj1zbYYF8lNgV9N_j0KpDAnFhW0d6_Pr1Q8iUwpgCsGdHH-fF_JhKBqnKlTpiAHDMYMpfUEGn05P5LL0qLuVLPoZxsXjO0tkdMtrjd8kIWAYpZ5QekAfefwWgQCm7Tw4o5AwEEyNyfdre6NY4m5hN6L641oXKJLq1cYUqrJuuT1xZOhN8stwkk7StQt8Z3axCF26cqdo93LpuVWsf7_uH5F6pa-8e7c5Dcv369Ko4Ty8WZ_Pi5CI1PAOZcru0iqllJqzMcqotV4xmDNTE2XypZK5K4YwER3NbciNsDipjQlgnLRgx4Yfk6TZ31Xff184HbCpvXF3rWGbtkWaSZ5xCBD9sQdN33veuxFVfNbrfIAUcZCMOsnGwh4M9HGTHDTlG2YhRNg6y4wxYLJDhLIY-3r2-XjbO_hG5tRuBJztAe6Prso-mK3_L8fhFNrkt96Oq3eavZv8t9o9ev-cYmm5DKx_cz32o7r-hyngm8fPbM3wn3ss3l-ev8BP_BQr9tJQ</recordid><startdate>2000</startdate><enddate>2000</enddate><creator>Karaberis, E.</creator><creator>Mourelatos, D.</creator><general>John Wiley & Sons, Inc</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>2000</creationdate><title>Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics</title><author>Karaberis, E. ; Mourelatos, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3705-3dbd626b74d5781ad362172069ed8b6586f4ec50e18df3c4d8067244de5d0c493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>9-nitro-20(S)-camptothecin</topic><topic>9-nitrocamtothecin</topic><topic>Animals</topic><topic>antineoplastic activity</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Phytogenic - pharmacology</topic><topic>Antineoplastic Agents, Phytogenic - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Camptothecin - administration & dosage</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Camptothecin - pharmacology</topic><topic>Camptothecin - therapeutic use</topic><topic>Cell Division - drug effects</topic><topic>cell kinetics</topic><topic>Chemotherapy</topic><topic>Drug Screening Assays, Antitumor</topic><topic>epirubicin</topic><topic>Epirubicin - administration & dosage</topic><topic>Epirubicin - pharmacology</topic><topic>Epirubicin - therapeutic use</topic><topic>Humans</topic><topic>Leukemia P388 - drug therapy</topic><topic>Lymphocytes - drug effects</topic><topic>Lymphocytes - ultrastructure</topic><topic>Medical sciences</topic><topic>melphalan</topic><topic>Melphalan - administration & dosage</topic><topic>Melphalan - pharmacology</topic><topic>Melphalan - therapeutic use</topic><topic>Mice</topic><topic>Pharmacology. Drug treatments</topic><topic>SCE</topic><topic>Sister Chromatid Exchange - drug effects</topic><toplevel>online_resources</toplevel><creatorcontrib>Karaberis, E.</creatorcontrib><creatorcontrib>Mourelatos, D.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Teratogenesis, carcinogenesis, and mutagenesis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karaberis, E.</au><au>Mourelatos, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics</atitle><jtitle>Teratogenesis, carcinogenesis, and mutagenesis</jtitle><addtitle>Teratog. Carcinog. Mutagen</addtitle><date>2000</date><risdate>2000</risdate><volume>20</volume><issue>3</issue><spage>141</spage><epage>146</epage><pages>141-146</pages><issn>0270-3211</issn><eissn>1520-6866</eissn><coden>TCMUD8</coden><abstract>Enhanced sister chromatid exchange (SCE) frequency by either melphalan (Mel) or epirubicin (Epir) was observed when human lymphocytes were exposed in vitro to 9‐nitro‐20(S)‐camptothecin (9NC). A correlation was observed between the magnitude of the SCE response and the depression of the cell proliferation index. The antitumor activity of Mel and of 9NC was tested on leukemia P‐388‐bearing mice. The two chemicals in combination enhance antitumor activity in a synergistic manner. Therefore, the in vivo antitumor effect of Mel in conjunction with 9NC appears to correlate well with the in vitro synergistic effect on SCE induction caused by the combined Mel plus 9NC treatment. Teratogenesis Carcinog. Mutagen. 20:141–146, 2000. © 2000 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>10820424</pmid><doi>10.1002/(SICI)1520-6866(2000)20:3<141::AID-TCM5>3.0.CO;2-D</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-3211 |
| ispartof | Teratogenesis, carcinogenesis, and mutagenesis, 2000, Vol.20 (3), p.141-146 |
| issn | 0270-3211 1520-6866 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17537310 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | 9-nitro-20(S)-camptothecin 9-nitrocamtothecin Animals antineoplastic activity Antineoplastic agents Antineoplastic Agents, Phytogenic - pharmacology Antineoplastic Agents, Phytogenic - therapeutic use Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Camptothecin - administration & dosage Camptothecin - analogs & derivatives Camptothecin - pharmacology Camptothecin - therapeutic use Cell Division - drug effects cell kinetics Chemotherapy Drug Screening Assays, Antitumor epirubicin Epirubicin - administration & dosage Epirubicin - pharmacology Epirubicin - therapeutic use Humans Leukemia P388 - drug therapy Lymphocytes - drug effects Lymphocytes - ultrastructure Medical sciences melphalan Melphalan - administration & dosage Melphalan - pharmacology Melphalan - therapeutic use Mice Pharmacology. Drug treatments SCE Sister Chromatid Exchange - drug effects |
| title | Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T20%3A55%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhanced%20cytogenetic%20and%20antitumor%20effects%20by%209-nitrocamptothecin%20and%20antineoplastics&rft.jtitle=Teratogenesis,%20carcinogenesis,%20and%20mutagenesis&rft.au=Karaberis,%20E.&rft.date=2000&rft.volume=20&rft.issue=3&rft.spage=141&rft.epage=146&rft.pages=141-146&rft.issn=0270-3211&rft.eissn=1520-6866&rft.coden=TCMUD8&rft_id=info:doi/10.1002/(SICI)1520-6866(2000)20:3%3C141::AID-TCM5%3E3.0.CO;2-D&rft_dat=%3Cproquest_cross%3E17537310%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3705-3dbd626b74d5781ad362172069ed8b6586f4ec50e18df3c4d8067244de5d0c493%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17537310&rft_id=info:pmid/10820424&rfr_iscdi=true |